title: Effectiveness of erythropoiesis on supervised intradialytic oral iron and vitamin C therapy is correlated with Kt/V and patient weight.
abstract: BACKGROUND
  Poor compliance to oral medication and diet is common in hemodialysis (HD) patients and limits the ability of oral iron therapy to support erythropoiesis. Intravenous (i.v.) iron may be associated with undesirable and sometimes life-threatening complications.
  
  
  METHODS
  We hypothesized that intradialytic oral iron therapy can overcome compliance problems and support effective maintenance erythropoiesis, which will keep Hct in the range of 33% to 36% and EPO requirements up to 50 units/week/kg. In a prospective observational study, SC EPO-treated hospital-based HD patients without conditions known to cause EPO resistance, were managed on intradialytic oral administration of iron and vitamin C. The primary endpoints were EPO requirements and resistance to EPO which standardized EPO requirements by the Hct level. Secondary endpoints included parameters that might affect the primary endpoints. Exclusion criteria were refusal to take oral medication, prestudy Hct < 27%, recent i.v. iron therapy or transfusions, bleeding, clinical conditions obligating Hct > 30% and known causes of EPO resistance. Twelve patients completed minimal follow-up period of 9 months.
  
  
  RESULTS
  Mean Hct was 34.4% (range: 31.8% - 40.2%). EPO requirements were 61.7 +/- 28.2 units/kg and below 52.5 units/kg in 50% of patients. Patients were classified into equal groups according to resistance to EPO, which was positively correlated (r = 0.71 p < 0.01) with body weight and Kt/V (r = -0.38, p < 0.05).
  
  
  CONCLUSIONS
  In conclusion, intradialytic oral iron therapy can support effective maintenance erythropoiesis in 50% of patients without known causes for EPO resistance. High response to EPO and low EPO requirement are correlated with lower body weight and possibly improved dialysis.
authors.affiliation: Department of Nephrology, Soroka Medical Center, Ben Gurion University of the Negev, Beer Sheva, Israel.
authors.forename: D
authors.initials: D
authors.lastname: Tovbin
authors.forename: A
authors.initials: A
authors.lastname: Markowitz
authors.forename: M
authors.initials: M
authors.lastname: Mostoslavsky
authors.forename: R
authors.initials: R
authors.lastname: Landver
mesh_terms: D000284:Administration, Oral; D018798:Anemia, Iron-Deficiency / Q000188:drug therapy* / Q000209:etiology; D001205:Ascorbic Acid / Q000008:administration & dosage*; D001835:Body Weight; D004920:Erythropoiesis; D006801:Humans; D007501:Iron / Q000008:administration & dosage*; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects
chemical_list: D007501:Iron; D001205:Ascorbic Acid